U.S. Markets closed

Agile Therapeutics, Inc. (AGRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8100-0.0300 (-1.06%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.8400
Open2.8200
Bid2.8100 x 1300
Ask2.8600 x 2900
Day's Range2.8100 - 2.8600
52 Week Range1.3500 - 4.7650
Volume714,058
Avg. Volume895,446
Market Cap246.156M
Beta (5Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Are Institutions Heavily Invested In Agile Therapeutics, Inc.'s (NASDAQ:AGRX) Shares?
    Simply Wall St.

    Are Institutions Heavily Invested In Agile Therapeutics, Inc.'s (NASDAQ:AGRX) Shares?

    A look at the shareholders of Agile Therapeutics, Inc. ( NASDAQ:AGRX ) can tell us which group is most powerful...

  • Is AGRX A Good Stock To Buy Now?
    Insider Monkey

    Is AGRX A Good Stock To Buy Now?

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • Agile Therapeutics' Q3 Focused on Launching Its New Contraceptive Patch
    Motley Fool

    Agile Therapeutics' Q3 Focused on Launching Its New Contraceptive Patch

    Investors can't complain about Agile Therapeutics' (NASDAQ: AGRX) stock performance so far this year. Agile Therapeutics doesn't have an approved product on the market yet. Agile announced Q3 total operating expenses of $14.7 million, a 227% jump from the $4.5 million reported in the prior-year period.